NEOVACS Obtains South Korea Health Authority Approval for IND Application With IFNa Kinoid in Lupus
April 14, 2016 10:52 ET
|
Neovacs, Inc.
PARIS, April 14, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that South Korea health...
2016 Financial Calendar
January 29, 2016 02:15 ET
|
Neovacs, Inc.
PARIS, Jan. 29, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its financial reporting...
Neovacs Secures €5 Million, From the Public Funding Program «Investments for the Future» to Support Clinical and Industrial Development for the Therapeutic Vaccine INFa Kinoïd
January 06, 2016 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), has concluded an agreement which provides non-dilutive funding of five million euros for over the next four...
Neovacs Signs a Strategic Partnering Agreement With the Korean Company CKD Pharmaceutical Corp.
December 15, 2015 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Dec. 15, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), today announced the signature of an exclusive licensing agreement with Chong Kun Dang (CKD) Pharmaceutical Corp....
Neovacs Reports First-Half 2015 Financial Results
October 02, 2015 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Oct. 2, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced its results for the six...
NEOVACS Initiates Phase IIb Trial of IFNa-Kinoid for the Treatment of Lupus
September 24, 2015 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Sept. 24, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today it has begun...
Neovacs Confirms Potent and Long-Lasting Biological Activity of IFNa-Kinoid 4 Years After Patient Dosing in Phase I/IIa Trial
September 09, 2015 02:15 ET
|
Neovacs, Inc.
Company Presented Extended Follow-Up Data on IFNα-Kinoid at 11th International Congress on Lupus
PARIS and BOSTON, Sept. 9, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader...
Neovacs Receives First Regulatory Approvals for a Phase IIb Trial of IFNa-Kinoid in Lupus
September 01, 2015 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, Sept. 1, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it has been...
Neovacs to Present at ChinaBio Partnering Forum
April 14, 2015 02:15 ET
|
Neovacs, Inc.
PARIS and BOSTON, April 14, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that is has been...
Neovacs Strengthens North American Presence With Formation of U.S. Subsidiary
March 23, 2015 03:15 ET
|
Neovacs, Inc.
PARIS, March 23, 2015 (GLOBE NEWSWIRE) -- NEOVACS (Alternext Paris:ALNEV, FR0004032746), a leader in active immunotherapies for the treatment of autoimmune diseases, is proud to announce the...